ADVANCING THE FRONTIERS OF CANCER SCIENCE AND MEDICINE

ORLANDO • APRIL 14-19
#AACR23 • AACR.ORG/AACR2023

CALL FOR ABSTRACTS

Abstract Submission Deadline: November 17, 2022
Late-Breaking and Clinical Trials Abstract Submission Deadline: January 12, 2023
Continuing Medical Education Activity - AMA PRA Category 1 Credits™ available
### TABLE OF CONTENTS

3  AACR Annual Meeting 2023 Key Dates  
5  Welcome  
6  Why You Should Attend  
7  Program  
11  Spotlight on Clinical Trials  
12  Professional Advancement Opportunities  
14  Exhibit Show  
15  Continuing Medical Education (CME)  
16  AACR Scientist↔Survivor Program®  
17  Press Coverage and Social Media  
18  Financial Support for Attendance  
20  Guidelines for Preparation and Submission of Abstracts  
24  Meeting Resources  
25  Abstract Categories  
30  AACR Membership Opportunities  
35  Housing  
37  Travel  
38  General Information  
40  AACR Annual Meeting 2023 Committees

### AACR Officers

**President**  
Lisa M. Coussens

**President-Elect**  
Philip D. Greenberg

**Immediate Past President**  
David A. Tuveson

**Treasurer**  
William N. Hait

**Chief Executive Officer**  
Margaret Foti

**Board of Directors**  
Nina Bhardwaj  
John D. Carpten  
Christina Curtis  
Luis A. Diaz, Jr.  
Silvia Chiara Formenti  
Elaine Fuchs  
Susan M. Galbraith  
Roy S. Herbst  
Thomas J. Lynch, Jr.  
Ira Mellman  
Lisa A. Newman  
William Pao  
Kimberly Stegmaier  
Suzanne L. Topalian  
Robert H. Vonderheide

### ABOUT THE COVER IMAGE:

The collaborative efforts of scientists and clinicians to prevent and cure cancer in all populations around the world are at the center of the AACR’s mission.

*Science images on front cover, left to right:*  
T cells, Getty Images; *Molecular Cancer Therapeutics* cover, March 2019; cancer cell division, Getty Images.

*Science images on back cover, left to right:*  
Human microbiome, Getty Images; *Cancer Immunology Research* cover Jan 2020; *Molecular Cancer Therapeutics* cover July 2020.

©2022 American Association for Cancer Research
## AACR ANNUAL MEETING 2023
### KEY DATES

<table>
<thead>
<tr>
<th>September 2022</th>
<th>December 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 15, 2022</td>
<td>December 2, 2022</td>
</tr>
<tr>
<td>Nomination Deadline for AACC Scientific Achievement Awards</td>
<td>Application Deadlines:</td>
</tr>
<tr>
<td>September 20, 2022</td>
<td>AACR Minority Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td>Membership Application Deadline for Early Access to Housing Reservations</td>
<td>AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td>September 27, 2022</td>
<td>AACR Women in Cancer Research Scholar Awards</td>
</tr>
<tr>
<td>Abstract Submission Opens</td>
<td>AACR Undergraduate Scholar Awards</td>
</tr>
<tr>
<td>September 27, 2022</td>
<td></td>
</tr>
<tr>
<td>Early Access to Housing Reservations Opens for Members</td>
<td></td>
</tr>
<tr>
<td>October 2022</td>
<td>December 9, 2022</td>
</tr>
<tr>
<td>October 4, 2022</td>
<td>Membership Application Deadline for Early Registration Rate</td>
</tr>
<tr>
<td>Housing Reservations Open to Nonmember Attendees</td>
<td></td>
</tr>
<tr>
<td>October 4, 2022</td>
<td>December 16, 2022</td>
</tr>
<tr>
<td>Application Deadline: NextGen Stars</td>
<td>Early Registration Deadline (lowest rates)</td>
</tr>
<tr>
<td>October 25, 2022</td>
<td>December 16, 2022</td>
</tr>
<tr>
<td>Meeting Registration Opens</td>
<td>Late-Breaking and Clinical Trials Abstract Submission Opens</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>November 2022</th>
<th>January 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 11, 2022</td>
<td>January 6, 2023</td>
</tr>
<tr>
<td>Membership Application Deadline for Prospective Regular Abstract Sponsors and Scholar-in-Training Award Applicants</td>
<td>Membership Application Deadline for Prospective Late-Breaking and Clinical Trials Abstract Sponsors</td>
</tr>
<tr>
<td>November 17, 2022</td>
<td>January 12, 2023</td>
</tr>
<tr>
<td>Regular Abstract Submission Deadline (11:59 p.m. ET)</td>
<td>Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)</td>
</tr>
<tr>
<td>November 17, 2022</td>
<td>January 17, 2023</td>
</tr>
<tr>
<td>Application Deadlines:</td>
<td>Online Itinerary Planner Available (tentative)</td>
</tr>
<tr>
<td>AACR Global Scholar-in-Training Awards</td>
<td></td>
</tr>
<tr>
<td>AACR Scholar-in-Training Awards</td>
<td></td>
</tr>
<tr>
<td>AACR Patient Advocates in Cancer Research Awards</td>
<td></td>
</tr>
</tbody>
</table>
### February 2023

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 2, 2023</td>
<td>Regular Abstract Status Notifications Sent</td>
</tr>
<tr>
<td>February 7, 2023</td>
<td><strong>Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts</strong></td>
</tr>
<tr>
<td>February 16, 2023</td>
<td>Late-Breaking and Clinical Trials Abstract Notifications Sent</td>
</tr>
<tr>
<td>February 17, 2023</td>
<td>Membership Application Deadline for Advance Registration Rate</td>
</tr>
<tr>
<td>February 20, 2023</td>
<td>Regular Abstract Withdrawal Deadline</td>
</tr>
<tr>
<td>February 24, 2023</td>
<td>Advance Registration Deadline (discounted rates)</td>
</tr>
<tr>
<td>February 28, 2023</td>
<td>Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition</td>
</tr>
</tbody>
</table>

### March 2023

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 3, 2023</td>
<td>Housing Reservation Deadline</td>
</tr>
<tr>
<td>March 6, 2023</td>
<td>Late-Breaking and Clinical Trials Abstract Withdrawal Deadline</td>
</tr>
<tr>
<td>March 10, 2023</td>
<td>Cancellation Deadline for Registration Refunds (less $125 processing fee)</td>
</tr>
</tbody>
</table>

### April 2023

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 7, 2023</td>
<td>Regular Abstract Titles and Texts Posted to Online Itinerary Planner (4:30 p.m. ET)</td>
</tr>
<tr>
<td>April 14, 2023</td>
<td>Late-Breaking and Clinical Trials Abstract Titles Posted to Online Itinerary Planner (4:30 p.m. ET); Abstract Texts Embargoed until April 14, 2023</td>
</tr>
<tr>
<td>March 23, 2023</td>
<td>Annual Meeting App Available for Download (tentative)</td>
</tr>
<tr>
<td>March 31, 2023</td>
<td>Registration Deadline: Undergraduate Student Caucus and Poster Competition</td>
</tr>
<tr>
<td>April 7, 2023</td>
<td>Membership Application Deadline to Register for the Annual Meeting at the Member Rate Onsite</td>
</tr>
<tr>
<td>April 14, 2023</td>
<td><strong>On-Site Registration Opens at Orange County Convention Center (12:00 p.m. ET)</strong></td>
</tr>
<tr>
<td>April 14, 2023</td>
<td><strong>AACR Annual Meeting Begins (3:00 p.m. ET)</strong></td>
</tr>
<tr>
<td>April 14, 2023</td>
<td>Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App</td>
</tr>
</tbody>
</table>
Dear Members and Friends of the AACR,

It is our pleasure to invite you to attend the 114th Annual Meeting of the American Association for Cancer Research (AACR), which will take place on April 14-19, 2023, in Orlando, Florida.

Over the past year, we have been celebrating the 115th anniversary of the AACR’s founding. Since its inception in 1907, the AACR has been at the forefront of every major discovery in cancer research – etiology, biology, prevention, detection, diagnosis, and treatment. The theme of this year’s meeting, “Advancing the Frontiers of Cancer Science and Medicine,” reflects the critical role that the AACR and its Annual Meeting play in defining the research agenda for the cancer field.

The excitement generated by last year’s return to an in-person meeting demonstrated that the connections and collaborations sparked by personal interaction are vital to innovation and continued progress against cancer. Therefore, while the major scientific sessions will again be made available virtually to meeting registrants, we urge you to make plans to join us in Orlando and engage in person with speakers, colleagues, and friends.

The Program Committee Vice Chairs and Cochairs have been working hard to develop a spectacular program that highlights cutting-edge advances in all areas of the field, including basic, translational, clinical, and population sciences, with a special focus on diversity and inclusion. We are grateful to all of the committee members for their expert guidance, and we look forward to sharing the results of their deliberations with you in April.

The Opening Plenary Session will address the theme of the meeting and set the tone for a week of groundbreaking science. Daily plenary sessions will focus on critical areas such as early detection and interception, immune ecosystems, new concepts in drug discovery and engineering, and the “30-year overnight sensation” of recent successes in targeting KRAS.

As part of our effort to explore and broaden the frontiers of cancer science, the meeting will showcase the exciting research being conducted by an emerging generation of cancer scientists. The Program Committee has identified investigators at the level of assistant professor whose discoveries are moving the field forward, and these new data will be highlighted. In addition, the NextGen Stars program—which offers early-career and early-stage scientists the opportunity to apply for oral presentation slots at the Annual Meeting—has been expanded to increase the variety of perspectives presented at the meeting. AACR Associate Members as well as Active Members at the assistant professor level or equivalent are welcome to submit an application and an extended abstract to the NextGen Stars program by October 4, 2022.

The robust scientific program will be preceded by a comprehensive slate of educational sessions and methods workshops. This educational program, which will begin at 3:00 p.m. on Friday, April 14 and run through Saturday, April 15, will present state-of-the-art concepts and technologies across the full spectrum of cancer science and medicine. Please keep the educational program in mind while registering and making your travel plans.

In addition to the program of invited speakers, the meeting will feature more than 6,000 presentation slots to accommodate proffered papers. As part of the AACR’s commitment to expanding opportunities for meritorious early-career scientists, the proffered program will include an increased number of oral presentations in Minisymposia, and some highly rated abstracts will be considered for presentation in major sessions. We encourage you and your colleagues to submit your abstracts by the November 17, 2022, deadline to be considered for oral or poster presentation.

We also anticipate that the proffered program will feature, as usual, more than two hundred clinical trials—including nearly 40 oral presentations in high-profile clinical sessions – Clinical Trial Plenary Sessions and Minisymposia. Clinical trialists are urged to consider the AACR Annual Meeting 2023 as a premier presentation outlet for their practice-changing work that will improve patient care. The submission deadline for clinical trials abstracts is January 12, 2023.

Please check the AACR website (AACR.org/AACR2023) regularly for program updates and announcements. We look forward to receiving your abstract submissions and to your active participation in AACR Annual Meeting 2023.

With very best wishes and regards,

Robert H. Vonderheide, MD, DPhil
Chair, 2023 Program Committee

Lisa M. Coussens, PhD, FAACR
President, 2022-2023

Margaret Foti, PhD, MD (hc)
Chief Executive Officer, AACR
Why You Should Attend the World’s Most Important Cancer Research Meeting

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population sciences, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year’s program, with the theme of “Advancing the Frontiers of Cancer Science and Medicine,” will be a comprehensive, cutting-edge scientific event that you will not want to miss!

The AACR Annual Meeting 2023 Will Highlight:

• **Educational Program**—More than 65 highly valuable Educational Sessions and Methods Workshops will once again be offered beginning on Friday, April 14. Access to these important sessions led by cancer experts is available to all attendees by purchasing the Educational Program Pass during registration.

• **Clinical Trials**—Included in the growing science-based clinical research program at the AACR Annual Meeting, clinical trials will once again be a part of Clinical Trials Plenary Sessions, Minisymposia, and Poster Sessions. More than 200 clinical trials were presented at last year’s Annual Meeting, including 37 oral presentations of highly rated abstracts.

• **NextGen Stars Program**—The NextGen Stars oral presentations will showcase early-career scientists who are AACR Associate Members and early-career and early-stage Active Members up to the level of assistant professor or equivalent. AACR is committed to providing early-career scientists with key opportunities to showcase their research and network with other cancer experts. To apply, submit your abstract and supporting materials by October 4, 2022. Details can be found at [AACR.org/AACR2023](http://AACR.org/AACR2023).

• **Wrap-Up Plenary Session**—The meeting will close with key opinion leaders presenting the most exciting highlights from the meeting and providing visionary remarks about cancer research opportunities in the future. The Wrap-Up Plenary Session will take place on Wednesday, April 19, 12:15 p.m.-1:30 p.m.

• **Fostering Entrepreneurship Forum**—Building upon the excitement and interest in the special entrepreneurship sessions held during the 2021 and 2022 AACR Annual Meetings, a new AACR Fostering Entrepreneurship Forum will start in the morning of April 13 and finish in the early afternoon of April 14, 2023, prior to the start of the Annual Meeting. The forum will feature a mix of educational sessions and networking opportunities for clinicians, researchers, and the investment community. Additional details will be available later this year on this exciting new program.

Why You Should Submit an Abstract

The AACR Annual Meeting is the premier event for presenting the cutting-edge cancer science that is shaping the future of cancer research and delivering cures to communities. Every abstract that is accepted for publication in the online *Proceedings* of the AACR is presented at the AACR Annual Meeting as a proffered paper, and all abstracts are considered for oral presentation in Minisymposia. Opportunities to give an oral presentation and simultaneously publish your work in a high-impact AACR journal are available for abstract presenters. See page 22 for more details.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2023 press program, which garners widespread national and international news coverage. See page 17 for more details.
Beginning at 3:00 p.m. on Friday, April 14, and continuing all day Saturday, April 15, 2023, a program of Educational Sessions and Methods Workshops will be presented. The program on Saturday will conclude with the Plenary Session titled, Beating KRAS: A 30-Year Overnight Sensation. The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 16. The meeting will conclude at 1:30 p.m. on Wednesday, April 19. The 2023 Program in Progress follows:

**Educational Program: Educational Sessions and Methods Workshops**

The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base in new and exciting fields. Add the Educational Program Pass to your registration to access this important program. The Educational Program consists of more than 65 unique sessions covering all areas of cancer research and features updates on critical topics and new technologies. As part of the 65 sessions, the following popular sessions will be included. Watch for more information at AACR.org/AACR2023.

- **Tumor Immunology and Immunotherapy for Nonimmunologists.** This exciting session is part of the yearly programming presented at the AACR Annual Meeting and organized in conjunction with the AACR Cancer Immunology Working Group. This popular session provides a comprehensive review of hot topics in the field and allows ample time for questions from the audience.

- **Chemistry to the Clinic.** This three-part series, organized in conjunction with the AACR Chemistry in Cancer Research Working Group, provides meeting attendees with foundational knowledge of critical elements of the cancer drug design and development process, such as lead optimization and identification of molecular targets and novel drug modalities.

- **Clinical Trial Design.** Over the course of three consecutive sessions, these Methods Workshops will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

Additional details will be posted at AACR.org/AACR2023.

**ABOUT THE IMAGE ABOVE**

Microsatellite-stable colorectal cancer (MSS CRC) is often resistant to immune checkpoint inhibitor treatment due to an immune-excluding and suppressive microenvironment. Wu et al. identified stromal chondroitin sulfate metabolism, specifically metabolism of the C-6-S subtype, as a driver of establishing an immune-exclusion barrier and polarizing suppressive macrophages via JAK/STAT and Hedgehog signaling in MSS CRC. Artwork by Lewis Long. *Cancer Immunology Research*, February 2022; 10(2).
Plenary Sessions

Saturday, April 15, 2023

Beating KRAS: A 30-Year Overnight Sensation

Chair: Dafna Bar-Sagi, NYU Langone Health, New York, NY
Dafna Bar-Sagi, NYU Langone Health, New York, NY
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
Beatriz M. Carreno, University of Pennsylvania, Philadelphia, PA
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Sunday, April 16, 2023

Opening Plenary Session: Advancing the Frontiers of Cancer Science and Medicine

Chair: Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, PA
Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY
David G. Denardo, Washington University School of Medicine in St. Louis, St. Louis, MO
Tomi Akinremi, Duke University School of Medicine, Durham, NC
Robert Yarchoan, National Institutes of Health, Bethesda, MD
Teresa A. Zimmers, Indiana University School of Medicine, Indianapolis, IN

Monday, April 17, 2023

Early Detection and Interception of Cancer

Chair: Peter Kuhn, University of Southern California, Los Angeles, CA
Phil H. Jones, Wellcome Sanger Institute, Cambridge, United Kingdom
Eun-Sil Shelley Hwang, Duke Cancer Institute, Durham, NC
Phillip G. Febbo, Illumina, Inc., San Diego, CA
Elana J. Fertig, Johns Hopkins University, Baltimore, MD
Karriem S. Watson, National Institutes of Health, Bethesda, MD

Tuesday, April 18, 2023

Embracing Immune Ecosystems

Chair: Judith A. Varner, UCSD Moores Cancer Center, La Jolla, CA
Florent Ginhoux, Agency for Science, Technology and Research (A*STAR), Singapore
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
Jose R. Conejo-Garcia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Gianpietro Dotti, University of North Carolina at Chapel Hill, Chapel Hill, NC
Dario A. Vignali, University of Pittsburgh School of Medicine, Pittsburgh, PA

Wednesday, April 19, 2023

New Concepts in Drug Discovery and Engineering

Chair: Sanjay V. Malhotra, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
Jennifer R. Cochran, Stanford University, Stanford, CA
Andrea L. Kasinski, Purdue University, West Lafayette, IN
Gregory R. Bowman, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Evan A. Scott, Northwestern University, Evanston, IL
Puja Sapra, AstraZeneca - MedImmune, LLC, Gaithersburg, MD

Wednesday, April 19, 2023

AACR Annual Meeting 2023 Highlights: Vision for the Future

Chair: Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, PA
Speakers to be announced
Major Symposia

25th Anniversary of Trastuzumab: Impact and Future Directions
Addressing the Global Oncology Disease Burden
Advances in Quantitative Sciences in Cancer: From Atomic Scale to Patients
Advances in Supportive Care
Artificial Intelligence at the Interface of Sparse Clinical Data and Big Laboratory Data
Biological Basis of Novel Targets for Solid Tumors
The Biology of Obesity, Aging, and Nutrition
Cancer Ecosystem and the Microenvironment
Cancer Stem Cells and Immuno-oncology
CAR T Cells in Solid Tumors
Cellular Therapies for Cancer
Clinical Opportunities and Challenges with Liquid Biopsies
Clinical Strategies for Myeloid Cell Modulation in Cancer
Complicity of Benign Cells in the Tumor Microenvironment
The Connection between Autoimmunity and Immunotherapy in Cancer
DNA Damage and Therapeutic Strategies
Electronic Health Records and Cancer Learning Health Systems
Future of Phase I Clinical Trials
Histone Alterations and Epigenetics as Cancer Drivers
Humoral Immune Response and Tertiary Lymphoid Structures in Cancer
Immunometabolism in the Tumor Microenvironment
Impact of Clonal Hematopoiesis in Cancer
Innate Lymphocytes and Cancer
Metabolic Influence on the Cancer Cell State
Microbiome and Cancer Immunotherapy
Molecular Mechanisms of KRAS Pathway Inhibitors
Myeloid Cells and Biological Responses in Cancer
New Horizons for T Cell Immunity and Checkpoints
New Insights into Cancer Initiation, Progression, and Therapy through Big Data Resources
Organ-Specific Regulation of Metastasis
Overcoming Drug Resistance
Pathogenesis of Childhood Cancers

Advances in Diagnostics and Therapeutics

Advances in FLASH Radiation
Cancer Vaccines: Back to the Future
Early Detection of Cancer and the Science of Early Cancer
Functional Precision Medicine
Immune Profiling and Immune Health in Cancer
Multiomics in Diagnosis and Care Management
New Approaches to Early Detection
Novel Computational Tools to Probe Cancer at the Single Cell Level
Novel Drug Design and Engineering
Surgical Advances with Chemical Probes and Intraoperative Imaging

Advances in Organ Site Research

Advances in Breast Cancer
Advances in Brain Tumors
Advances in Gastrointestinal Malignancies
Advances in Leukemia Research and Treatment
Advances in Lymphoma
Advances in Melanoma Research and Treatment
Advances in Non-Small Cell Lung Cancer
Advances in Ovarian Cancer
Advances in Pancreas Cancer
Advances in Prostate Cancer
Advances in Sarcoma Biology
Advances in Small Cell Lung Cancer and Neuroendocrine Cancer
**Advances in Population Sciences**
- Behavioral Economics and Psychology to Improve Cancer Care
- Cancer and COVID-19 Vaccination
- Population Sciences in the Era of Omics

**Advances in Prevention Research**
- Advances in Cancer Screening and Prevention
- Germline Genetics and Cancer Predisposition
- The Science Driving Novel Treatment of Nicotine Addiction
- Strategies for Cancer Interception

**Advances in the Science of Cancer Disparities**
- Achieving Equitable Access to Cancer Care
- The Biology Driving Cancer Disparities
- Disparities and Cancer Outcomes

**Forums**
- CAR Cells: Which CAR to Drive?
- Has Adding Anti-PD1/PDL1 to Other Treatments Lived Up to the Hope?
- How Can We Improve Data-Sharing?
- How Can We Improve Workforce Recruitment and Retention?
- How Can We Make Cancer Care at Home the Norm and Not the Exception?
- What Are the Challenges and Solutions in Adolescent and Young Adult Cancers?
- What Does a Biostatistician Really Think of Your Study and Why?
- What Is the Best Way to Engage Diverse Communities in Cancer Research?
- What Is the Future of Antiangiogenesis?
- What Is the Utility of PDX and Organoid Models in the Era of Immuno-oncology?

**Science and Public Policy Program**

Decisions made by policy makers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policy makers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The **Science and Health Policy Track** includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases.

Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The **Regulatory Science and Policy Track** includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The **Science of Survivorship Track** includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite trans-sector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship in vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.
Submit Your Clinical Trials Abstracts to the AACR Annual Meeting 2023

Become a part of our growing science-based clinical research program at the AACR Annual Meeting and help us showcase how research continues to transform the lives of cancer patients.

Why You Should Submit

• Numerous and unique oral presentation opportunities, including:
  - Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
  - Three Clinical Trials Minisymposia
• Poster presentations
• Opportunities for extensive national media coverage through the AACR press program
• Opportunities to publish a manuscript in one of the AACR’s highly regarded journals, including possible simultaneous publication with your abstract presentation
  - Indicate your intention to submit a manuscript related to your abstract during the abstract submission process
  - Contact aacrpublications@aacr.org with any questions
• No restrictions on presenters if the presentation is CME-compliant

What to Submit

• Any phase (first in-human, I, II, III, or any combination) abstract from national or international clinical trials
• Trials for solid tumors or blood cancers in adult and pediatric patients
• Promising ongoing trials, or unique trial designs that have not yet yielded results. Select the Clinical Trials in Progress category (CT01).
• Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the AACR Clinical Trials Committee).
• See page 27 for clinical trials (CT) abstract categories and visit AACR.org/AACR2023 for submission guidelines.

When to Submit

• Submit your completed or placeholder abstract(s) by the January 12, 2023 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 17, 2022 deadline.
• Final results and conclusions for placeholder abstracts are due by February 7, 2023.

AACR Annual Meeting 2022

37 CLINICAL TRIALS ABSTRACTS PRESENTED IN PLENARY SESSIONS AND MINISYMPOSIA
113 CLINICAL TRIALS ABSTRACTS PRESENTED IN POSTER SESSIONS
71 CLINICAL TRIALS IN PROGRESS ABSTRACTS PRESENTED IN POSTER SESSIONS
221 TOTAL CLINICAL TRIALS ABSTRACTS PRESENTED
In support of its mission to promote the education and training of cancer scientists and clinicians, and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides AACR Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to advance their careers. For more information about any of the professional development opportunities that follow, visit AACR.org/AACR2023 and click on the “Professional Development Opportunities” tab.

NextGen Stars

Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2023. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career and early-stage scientists at the AACR Annual Meeting and to support their professional development and advancement.

The deadline to submit applications is 5:00 p.m. U.S. ET, October 4, 2022. Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2023 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2023 under the “NextGen Stars” tab.

Professional Advancement Sessions

Exclusive Member Benefit

Professional Advancement Sessions have long been an integral part of the AACR Annual Meeting experience and dedication to the education, training, and career advancement of cancer research investigators at all stages of their careers. A collaborative effort each year by the AACR Science Education and Career Advancement Committee, Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, Associate Member Council (AMC), and the AACR Publications Committee, these sessions provide several interactive and engaging professional development and career advancement opportunities to investigators at all levels, including students, early-career scientists, and early-stage investigators.

All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as an Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research) or Student Member (undergraduate and high school students). If you are not an AACR member, you are strongly encouraged to join the AACR and take advantage of the opportunity to attend these sessions and the many other benefits of membership, including the privilege of sponsoring abstracts, significantly reduced member registration rates, and more. Visit AACR.org/Membership to apply today!

Professional Advancement Sessions to be held at the Annual Meeting 2023 will be announced in the fall. Visit AACR.org/PAS for session updates.
CancerCareers.org

AACR’s CancerCareers.org is a year-round career resource offering unparalleled career services and opportunities to cancer biomedical researchers and clinicians seeking to advance their scientific careers, and to employers who are seeking to recruit highly qualified scientists. For more information, visit CancerCareers.org or email customerservice@cancercareers.org.

AACR Annual Cancer and Biomedical Research Career Fair

The AACR Annual Cancer and Biomedical Research Career Fair takes place at the AACR Annual Meeting in Orlando, Florida on Saturday, April 15, 2023, from 9:00 a.m. to 3:00 p.m. ET. Visit CancerCareers.org for more information or to register for the 2023 Career Fair (AACR.org/careerfair), or email careerfair@aacr.org.

Employers will be able to:
• Meet scientists at all professional levels
• Post open positions
• Review CVs/resumes

Job seekers will be able to:
• Meet employers face-to-face from academic institutions, industry, and government institutions
• Upload their CVs/resumes on CancerCareers.org
• Sign up for Job Alerts

CancerCareers Hub

The AACR provides Career and Professional Development opportunities to scientists at all career levels at the CancerCareers Hub. AACR will host several Career Development and recruiting events at the Annual Meeting 2023 beginning on Sunday, April 16 through Wednesday, April 19, 2023, in the CancerCareers Hub, located in the Orange County Convention Center.

The CancerCareers Hub is open during the following hours:
• Sunday, April 16: 9:00 a.m.-5:00 p.m.
• Monday, April 17: 9:00 a.m.-5:00 p.m.
• Tuesday, April 18: 9:00 a.m.-5:00 p.m.
• Wednesday, April 19: 9:00 a.m.-12:00 p.m.

Create your FREE jobseeker profile account to search for positions, post your CV/resume, create Job Alerts, and take advantage of other features. For more information, visit CancerCareers.org or email customerservice@cancercareers.org.

“It was GREAT to be at an IN PERSON event.”
The 2023 AACR Exhibit Show will include a wide array of companies with the latest products and services for laboratory and clinical research. Additional areas of interest include the Nonprofit Section, AACR Publications and Publisher’s Row, AACR Advocacy Partners’ Pavilion, Exhibitor Spotlight Theaters, and AACR Central, which is the main hub for AACR services.

The exhibits, located adjacent to the poster sessions, make a significant contribution to the educational value of the meeting. Please add time to your overall schedule to visit the Exhibit Show. Complimentary coffee, tea, and soft drinks will be served in the Exhibit/Poster Hall at specified times on each day when exhibits are open.

In addition, great opportunities to connect with exhibitors and other attendees will be available in the Exhibit Hall.

- Exhibitor-hosted refreshment breaks, featuring a wide variety of specialty snacks, will be served on Monday and Tuesday afternoon. These provide networking opportunities with exhibitors located in these break areas.

- Be sure to participate in Explore!, available through the AACR Annual Meeting App. By visiting participating exhibitors, you will be entered to win an Amazon gift card. Additional information will be available in the App and AACR website.

- Located in the Exhibit Hall, the Exhibitor Spotlight Theaters are reserved by exhibiting companies to present their latest products and services in special 60-minute sessions during exhibit hours. For a full list of presentations, please refer to the AACR Annual Meeting 2023 App.

If your organization would like to exhibit and would like to receive an Exhibitor Prospectus, please contact the Exhibits Team at 215-440-9300 or by email at exhibits@aacr.org.

“There was a wide array of sessions and vendors. Excellent poster sessions.”
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2023 will be a Continuing Medical Education Activity and AMA PRA Category 1 Credits™ will be available. This is a great opportunity to complete your required credit hours.

Meet Your MOC Point Requirements

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2023. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine's (ABIM) Maintenance of Certification program.

“
There were many excellent talks to attend – I felt like there was always something to do at this meeting.”

”
Commitment to Cancer Survivors and Patient Advocates

Patient advocates play a crucial role in cancer research. They educate the public about new research discoveries, partner with scientists on cancer research, guide health and regulatory policies, and raise precious funds for cancer research. The AACR celebrates the contributions of patient advocates to cancer research and encourages their attendance and participation at the AACR Annual Meeting.

Patient advocates are offered discounted registration rates to attend the AACR Annual Meeting.

AACR Scientist↔Survivor Program® at the Annual Meeting

Now in its 25th year, the AACR Scientist↔Survivor Program® (SSP) at the Annual Meeting is an education program for patient advocates. Led admirably since its inception by Anna D. Barker, PhD, FAACR, of the Lawrence J. Ellison Institute for Translational Medicine, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process which will open in October 2022.

The unique program provides an opportunity for patient advocates to learn about cancer research and network with scientists, physicians, health care professionals, and other advocates. Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year’s SSP, please visit AACR.org/SSP2023 or email advocacy@aacr.org.

Patient Advocacy Programs at the AACR Annual Meeting

AACR offers a number of opportunities to encourage bidirectional communication between researchers and patient advocates at the Annual Meeting, including the AACR Partners Pavilion, patient advocate abstracts, Patient Advocates in Research Awards, and patient advocate forums. For more information, please visit AACR.org/patient-advocacy.
Attracting Journalists Worldwide, Generating Major News Coverage

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Annual Meeting 2022 attracted nearly 220 registered reporters and generated more than 4,700 media clips in leading consumer and trade outlets including USA Today, STAT, Science, and Forbes, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2023 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@aacr.org or Rick Buck at rick.buck@aacr.org.

Utilizing Social Media to Amplify the Conversation

The AACR Annual Meeting 2022 also generated significant social media activity in the cancer research community. Social media highlights included:

- 7,000+ people joining the conversation on Twitter
- 29,000+ tweets about the meeting
- 236,500,000 total impressions

“The content of the meeting and execution were excellent, everything I have come to expect from AACR.”
Through the generosity of its loyal supporters, the AACR is pleased to provide financial support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria, is available below.

**AACR Scholar-in-Training Awards**

**Exclusive Member Benefit**

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious proffered papers at the AACR Annual Meeting 2023. These awards are made possible by the generosity of supporting foundations and corporations. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by **November 11, 2022**. The AACR Membership Application Form is available on the AACR website at [AACR.org/Membership](http://AACR.org/Membership). To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. For details of the application process and the selection criteria, please visit [AACR.org/SITA](http://AACR.org/SITA). Application deadline: **November 17, 2022**.

**AACR Global Scholar-in-Training Award**

Global Scholar-in-Training Awards (GSITA) are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2023 and then complete a separate GSITA application. Applicants must be Associate Members of the AACR in good standing (membership current through 2022). Student Members completing a Bachelor of Medicine, Bachelor of Surgery (MBBS) or other international undergraduate medical degree equivalent to an advanced medical degree in the United States, are also welcome to apply. Nonmember undergraduate students pursuing an international medical degree, graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a GSITA should submit a Membership Application Form by **November 11, 2022**, before submitting their GSITA application. For additional details and a list of eligible countries, visit [AACR.org/GSITA](http://AACR.org/GSITA). Application deadline: **November 17, 2022**.

**AACR Patient Advocates in Cancer Research Awards**

AACR Patient Advocates in Cancer Research Awards are available to patient advocates presenting meritorious abstracts at the AACR Annual Meeting. To apply for this award, an applicant must first submit an abstract, and then complete a separate award application and patient advocate verification form. For more information, please visit [AACR.org/patient-advocacy](http://AACR.org/patient-advocacy). Application deadline: **November 17, 2022**.
AACR Minority and Minority-Serving Institution Faculty (MMSIF) Scholar in Cancer Research Awards

Full-time underrepresented minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at the AACR Annual Meeting are encouraged to apply for this meritorious scholar award.

These awards are intended to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada, or scientists who are permanent residents of these countries, may receive one of these awards. For details or to submit an application, visit AACR.org/MSI. Application deadline: December 2, 2022.

AACR Minority Scholar in Cancer Research Awards

Presenters of proffered papers who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award. This program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada, or scientists who are permanent residents of these countries, may receive one of these awards. For details or to apply, visit AACR.org/MSA. Application deadline: December 2, 2022.

AACR-Women in Cancer Research (WICR) Scholar Awards

The AACR-Women in Cancer Research (WICR) Scholar Award is a highly competitive award recognizing WICR members who are scientists-in-training and presenters of meritorious scientific papers at the AACR Annual Meeting. The purpose of this award is to increase the scientific knowledge base of WICR members and to encourage them to pursue careers in cancer research. Eligible candidates encouraged to apply include AACR-WICR members who are graduate students, medical students, residents, clinical fellows, and postdoctoral fellows. Nonmembers are encouraged to join. For details or to apply, visit AACR.org/WSA. Application deadline: December 2, 2022.

AACR Undergraduate Scholar Awards

The AACR is pleased to offer this highly competitive award program, which is intended to inspire young, third-year science students to enter the field of cancer research and to provide a unique educational opportunity for these students in the development of their careers in science. Selected students will receive scholar awards to participate in two consecutive AACR Annual Meetings. To learn more about this award program, visit AACR.org/UndergradAwards. Application deadline: December 2, 2022.

“...I thoroughly enjoyed the sessions and educational sessions as well! The MICR sessions and platform have inspired me to focus on particular things in my career as a scientist.”
Proffered Paper Presentation Format

All proffered papers that are accepted for poster or oral presentation at the AACR Annual Meeting 2023 must be presented in person. Posters will not be presented in electronic format, and remote minisymposium presentations will not be permitted. Presenters who are unable to travel to Orlando to present their proffered paper in person will have the opportunity to designate a coauthor to serve as the presenter. If no coauthors are available to present the paper in person, the abstract must be withdrawn.

IMPORTANT: Publication of Abstracts in Cancer Research

In previous years, abstracts accepted for presentation at the AACR Annual Meeting were published in an online-only Proceedings supplement to the AACR journal Cancer Research after the conclusion of the meeting. Beginning in 2023, the Proceedings supplement will be published prior to the meeting in two parts. Part 1 of the online Proceedings (regular abstracts) will be published on Friday, March 31, and Part 2 (clinical trials and late-breaking abstracts) will be published on Friday, April 14. Revised Proceedings supplements containing the full text of embargoed abstracts as well as any late change will be published in Cancer Research approximately one month after the meeting.

Once the abstracts are published in the journal, additional requests, edits, and withdrawals cannot be processed. Therefore, abstract authors should carefully read their abstracts before submission to ensure that all authors are listed correctly and that the text is correct. All requests to withdraw or edit abstracts must be received by the following deadlines:

- Regular Abstracts (submitted by the November 17 deadline): Monday, February 20, 2023
- Clinical Trials and Late-Breaking Abstracts (submitted by the January 12 deadline): Monday, March 6, 2023

Special Interest Submissions

The AACR encourages submission of abstracts in the following categories, which will be given special consideration for oral presentation at the AACR Annual Meeting 2023:

- Cancer Disparities and Inequities Research. This abstract subcategory is included in the Population Sciences (PS), Prevention, Early Detection, and Interception (PR), COVID-19 and Cancer (COVID), and Science and Health Policy (SHP) categories (see pages 25-29).
- Studies Using Data from AACR Project GENIE. While there is no specific abstract category for abstracts that describe work using AACR Project GENIE, you can have your abstract considered by selecting “AACR Project GENIE” as one of your keywords during the submission process.
- Precision Combination Therapy. This abstract subclassification is included in the Precision Oncology subcategory (CL09) in the Clinical Research (CL) category (see page 26).
- Global Health. While there is no specific abstract category for these abstracts, you can have your global health abstract considered by selecting “Global Health” from the abstract keyword list during the submission process.
AACR Abstract Submission System

Authors must submit abstracts for presentation at the AACR Annual Meeting 2023 using the AACR Abstract Submission System, which will be available at AACR.org/AACR2023 beginning September 27, 2022. You can create, modify, and submit abstracts until the November 17, 2022, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

The Abstract Submission System has been optimized for the current versions of most browsers. Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or aacr@support.ctimeetingtech.com.

Responsibilities of Authors

By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

• Support for Abstract/Verification of Authorship. All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. Authors will be notified of their inclusion on an abstract via email.

• Sponsorship of Abstracts. The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 23 for Abstract Sponsorship Regulations.

• Transfer of Copyright. On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

• Presentation of Abstracts. All proffered papers scheduled for presentation at the AACR Annual Meeting 2023 must be presented in person. The submitting author for each abstract must designate a presenter who agrees to register for the meeting and attend the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot attend the meeting, the authors are expected to designate a replacement or withdraw the abstract (see page 23).

• Confirmation of No Prior Publication/Presentation. Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2023.

Exceptions: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 12, 2023, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented. Any other exceptions to this policy are at the discretion of AACR leadership.

Content of Abstracts

Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).

Abstract Control Number and Abstract Presentation Number

An Abstract Control Number (e.g., 23-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

The Control Number is for internal reference only. If your abstract is accepted for presentation, it will be assigned a permanent Presentation Number that will be used to identify it in all online and print abstract materials. Please place the Presentation Number on your poster and use it in citations of your published abstract. Do not place the Control Number on your poster.

Financial Relationships of Coauthors

Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of each of your coauthors. For more information on financial relationships, visit AACR.org/CME.
Sponsor Permission and Information
Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 23.

Length of Abstracts
The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

Abstract Category, Subcategory, and Subclassification
You must select a category, subcategory, and subclassification for your abstract. See pages 25-29 for details.

Disclosure of Chemical Structures
At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocrystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required.

The Annual Meeting Program Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for presentation; however, a limited number of these abstracts without chemical structures may be accepted for presentation if deemed to be of sufficient scientific merit.

Submission Fee
Each abstract submitted must be accompanied by a US$75 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

Abstract Deadline
The deadline for abstract submissions is 11:59 p.m. U.S. ET, Thursday, November 17, 2022. Abstracts submitted after the deadline will not be considered by the Program Committee. No significant changes may be made to abstracts after the November 17, 2022, deadline.

NOTE: Submitting an abstract for presentation at the AACR Annual Meeting 2023 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at AACR.org/AACR2023.

Late-Breaking Abstract Deadline
The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Thursday, January 12, 2023. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

Clinical Trials Abstract Deadline
The deadline for clinical trials abstracts (including placeholder abstracts) is 11:59 p.m. U.S. ET, Thursday, January 12, 2023. Final data for placeholder abstracts are due Tuesday, February 7, 2023. Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

Publication Opportunities
During the abstract submission process, you may indicate your interest in submitting a manuscript based on your meeting abstract. Manuscripts submitted by the deadlines noted in the FAQ (AACR.org/AACR2023Journals/) can be considered for publication simultaneously with the AACR’s Annual Meeting, provided major revisions are not required. In addition, manuscripts can be considered for publication beyond the simultaneous opportunity. For more information on all publication opportunities in an AACR journal, please contact the AACR Publishing Division at aacrpublishing@aacr.org.
GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS (cont’d)

Presentation of Proffered Papers at the AACR Annual Meeting

Every proffered abstract that has been accepted for publication in the online Proceedings must have a corresponding in-person presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Scientific Programs Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Scientific Programs Department at abstractchanges@aacr.org. Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

• The withdrawal of the abstract from the session
• The removal of the abstract from the online Proceedings
• The loss of future sponsorship privileges for the sponsor of the abstract
• The loss of future abstract submission/authorship privileges for the presenter of the abstract

Deadline for Withdrawal of Abstracts

Requests to withdraw regular abstracts will be accepted through Monday, February 20, 2023. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through Monday, March 6, 2023. Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

Abstract Sponsorship Regulations

Expanded Abstract Sponsorship Privileges for AACR Members

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 17 regular abstract deadline, member dues must be paid in full through 2022. To be in good standing for the January 12 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2023. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.

1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing (dues paid or eligibility recertified). (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.

3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts.

4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are not required to provide an endorser.)

5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.

6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE AUTHORS. Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee.

Membership Application Deadlines for Abstract Sponsorship

Nonmember individuals interested in joining the AACR and sponsoring an abstract for AACR Annual Meeting 2023 must submit an application for membership no later than November 11, 2022. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 6, 2023. Membership questions may be directed to membership@aacr.org.
AACR Annual Meeting Program/Navigation

AACR Annual Meeting attendees can use the following electronic and print resources to plan their itineraries and navigate the meeting:

• **Online Itinerary Planner (available January 17, 2023).** Search all AACR Annual Meeting presentations (including all proffered abstracts beginning March 14, 2023) by author/speaker, title word, and keyword and create a personal itinerary for the meeting. Personal itineraries created in the Itinerary Planner can be exported as an iCalendar file into attendees’ personal Outlook, Google Calendar, or Apple iCal applications. Itineraries can also be imported into the AACR Annual Meeting App (see below).

• **AACR Annual Meeting App (available March 24, 2023).** Attendees can carry the AACR Annual Meeting wherever they go—with or without a network connection. The AACR Annual Meeting App is available in native versions to serve users of iPhone, iPad, and Android devices and also in a browser-based version for use on most web-enabled smartphones and tablets. Once downloaded, all App content and functionality is stored locally on the user’s Apple or Android device and can be accessed without an Internet connection—including the full text of more than 6,000 abstracts. Users can search, browse, and select sessions to create a personal itinerary for the meeting. They can also import their itineraries from the Online Itinerary Planner (see above).

• **Print Program Guide.** All attendees receive a portable Program Guide containing the dates, times, locations, and titles of all AACR Annual Meeting sessions. The Program Guide also contains the names of the chairs and invited speakers in each session as well as the titles of all invited presentations. More detailed program information (including the Minisymposium and Poster Session presentations) is available in the electronic versions of the program (see above).

Please Note: As of 2023, there will no longer be a print Guide to Poster Sessions and Exhibits. Poster and Exhibit information is available to attendees through the Meeting App. A list of exhibitors and booth numbers is also included in the Print Program Guide.

AACR Annual Meeting Abstracts

The following electronic and print resources are available to attendees who wish to access the proffered abstracts accepted for presentation at the AACR Annual Meeting:

• **Online Proceedings/Itinerary Planner (abstracts available March 14, 2023).** The Online Proceedings/Itinerary Planner provides fully searchable access to the full text of all proffered abstracts (see above).

• **AACR Annual Meeting App (available March 24, 2023).** The full text of all proffered abstracts is stored natively in the AACR Annual Meeting App (see above).

• **Mobile Proceedings (available April 10, 2023).** The mobile edition of the Proceedings of the AACR Annual Meeting contains the full text of all regular proffered abstracts (clinical trials and late-breaking abstracts are not included). The mobile edition is available in mobi, e-pub, and PDF file formats for download to devices such as the Amazon Kindle, iPad, iPhone, iPod Touch, Sony Reader, and the Barnes & Noble Nook.

• **Online Supplement to Cancer Research (available March 31, 2023).** All presented abstracts will be published as an online-only supplement to the AACR journal Cancer Research. Regular abstracts will be published on March 31, 2023, and clinical trial and late-breaking abstracts will be published on April 14, 2023.

Please Note: Due to declining demand, the print Proceedings is no longer offered for purchase to AACR Annual Meeting attendees.
The AACR Annual Meeting 2023 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2023. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is November 17, 2022 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is January 12, 2023 (11:59 p.m. ET).

The abstract categories are listed in alphabetical order.

**BCS Bioinformatics, Computational Biology, Systems Biology, and Convergent Science**

**BCS01 Bioinformatics, Computational Biology, and Systems Biology**
(See also MCB08: Genomics)
- Analytic pipeline optimization
- Application of bioinformatics to cancer biology
- Artificial intelligence and machine/deep learning
- Database resources
- Integrative computational approaches
- Molecular modeling
- New algorithms
- New software tools for data analysis
- Sequence analysis
- Statistical methods
- Systems engineering
- Whole cell modeling
- Other

**BCS02 Convergent Science**
- Artificial intelligence and machine/deep learning
- Digital pathology
- Early detection and imaging
- Integration of clinical and research data
- Integrative cancer science
- Liquid biopsy: Multi-analyte and multi-omic
- Mathematical modeling
- Network biology and precision medicine
- Physical sciences in oncology
- Other

**CH Chemistry**

**CH01 Drug Discovery, Design, and Delivery**
- Basic and applied nanotechnology and therapeutics
- Chemoinformatics, in silico screening, and computational methods
- Drug delivery
- Drug design
- High-throughput screening (assays and libraries)
- Lead identification
- Lead optimization
- Nanotechnology drug delivery
- Natural products
- Synthesis, metabolism, and disposition
- Other

**CH02 Proteomics and Mass Spectrometry**
- Biological mass spectrometry and systems biology
- Proteomics and biomarker discovery
- Proteomics and signaling networks
- Other

**CH03 Structural and Chemical Biology**
- Chemical genetics and genomics
- Nanotechnology in chemical biology
- Small molecule, protein, and nucleic acid interactions
- Target identification, small molecule probes, and libraries
- X-ray and NMR structures
- Other
<table>
<thead>
<tr>
<th>CATEGORIES</th>
<th>CL</th>
<th>Clinical Research (not including clinical trials, see also the Clinical Trials (CT) categories)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL01</td>
<td>Biomarkers</td>
<td>Biomarkers predictive of therapeutic benefit, Diagnostic biomarkers, Early detection biomarkers, Liquid biopsies: Circulating nucleic acids, Liquid biopsies: Circulating tumor cells, Metastasis biomarkers, Prognostic biomarkers, Spatial proteomics and transcriptomics</td>
</tr>
<tr>
<td>CL02</td>
<td>Biostatistics in Clinical Trials</td>
<td>Design and analysis of clinical trials, New study designs: Theory, methodology, and modeling, Statistical modeling for cancer studies</td>
</tr>
<tr>
<td>CL03</td>
<td>Clinical Endocrinology (See also EN01: Molecular, Preclinical, and Clinical Endocrinology)</td>
<td>Endocrine-related cancers, Growth factors, receptors, and signal transduction, Hormone receptors and diagnosis/prognosis, Hormone signaling and inhibitors, Hormone synthesis, metabolism, and inhibitors, Neuroendocrine and other endocrine factors, Nuclear receptors: Structure and function, Preclinical studies of endocrine-related cancers, Receptors and signal transduction, Steroid hormone receptors</td>
</tr>
<tr>
<td>CL04</td>
<td>Clinical Outcomes Research</td>
<td>Clinical outcomes research</td>
</tr>
<tr>
<td>CL05</td>
<td>Clinical Research in the Elderly</td>
<td>Aging, immunity, and cancer</td>
</tr>
<tr>
<td>CL06</td>
<td>Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations</td>
<td>Biobanking/biospecimen collection, Clinical trial design, Community-engaged research/community-participatory research, Community outreach and patient accrual, Impact of COVID-19 on patient accrual</td>
</tr>
<tr>
<td>CL07</td>
<td>Immuno-oncology (See also ET01: Biological Therapeutic Agents; IM01: Preclinical Immunotherapy)</td>
<td>Adoptive cell therapy, Combination immunotherapies, Immune checkpoints, Immune mechanisms invoked by other therapies including chemotherapy, Immune mechanisms invoked by radiation therapy, Immune monitoring/clinical correlates, Immune response to therapies, Immunomodulatory agents and interventions, Inflammation, immunity, and cancer, Modifiers of the tumor microenvironment, Therapeutic antibodies, including engineered antibodies, Vaccines (oncolytic and prophylactic)</td>
</tr>
<tr>
<td>CL08</td>
<td>Pediatric Cancer – Clinical Investigations (See also CT09: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB06: Pediatric Cancer - Basic Science)</td>
<td>Adolescent and young adult oncology, Childhood cancer drug development, Immunotherapeutic approaches to pediatric cancer, Pediatric cancer predisposition and surveillance, Survivorship, late effects, and second cancers, Therapeutic dosing, resistance, and combination therapy application, Translational pediatric cancer research</td>
</tr>
<tr>
<td>CL09</td>
<td>Precision Oncology</td>
<td>Combination therapy, Molecular targeted therapy</td>
</tr>
<tr>
<td>CL10</td>
<td>Radiation Oncology (See also ET08: Radiation Science: ET07: Radiation Radiotherapeutics)</td>
<td>Clinical radiotherapeutic studies, Interventional radiotherapy, Modification of radiosensitivity, Radiation-immunotherapy and other radiotherapeutic combinations, Radiation-induced late effects/second cancers, Radiation-induced resistance</td>
</tr>
<tr>
<td>CL11</td>
<td>Real-World Data and Real-World Evidence</td>
<td>Analyses using clinico-genomic databases, Clinical informatics and data science, Retrospective clinical analyses</td>
</tr>
<tr>
<td>CL12</td>
<td>Surgical Oncology (including Prophylactic Surgery)</td>
<td>Surgical oncology</td>
</tr>
<tr>
<td>CL13</td>
<td>Survivorship Research and Supportive Care</td>
<td>Biology of cell and tissue damage, Cardio-oncology, Comparative effectiveness research and cost-effective studies, Late effects of cancer and its treatment, including second cancers, Psycho-oncology, Supportive care, palliation, and pain management, Translational survivorship research</td>
</tr>
<tr>
<td>CL14</td>
<td>Translational Research – Molecular Biology in Clinical Oncology (See also TB03: In Vivo Imaging)</td>
<td>Clinical imaging, Clinical radionuclide theranostics, Cytogenetics and clinical molecular genetics, Epigenetic therapy, Functional and molecular imaging, Laboratory correlates for targeted agents, Molecular classification of tumors, Radiomics, Tumor staging: Correlation of clinical and molecular markers</td>
</tr>
</tbody>
</table>

**COVID**

<table>
<thead>
<tr>
<th>COVID-19 and Cancer</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID01</td>
<td>COVID-19 and Cancer</td>
</tr>
<tr>
<td></td>
<td>Cancer drug repurposing to treat COVID-19, Cancer prevention and early detection during the COVID-19 pandemic, Clinical trials [See also CT02: COVID-19, Cancer, and Clinical Trials (Phase I–Phase IV and Trials in Progress)], Continuity of cancer care, COVID-19 vaccines and immune responses among cancer patients, Effects of cancer immunotherapies on patients with COVID-19 (with or without cancer), Effects of COVID-19 on cancer survivorship, Epidemiology and registries of COVID-19 and cancer (including biorepositories), Health inequities and disparities during the COVID-19 pandemic, Intersection of the biology of SARS-CoV-2 and cancer, Risk factors and comorbidities resulting in adverse outcomes for cancer patients with COVID-19</td>
</tr>
</tbody>
</table>

**LATE-BREAKING TALKS**

**Deadline:**
- Early-Breaking and Clinical Trials Abstract Submission Deadline: **January 12, 2023 (11:59 p.m. ET)**
- Late-Breaking and Clinical Trials Abstract Submission Deadline: **November 17, 2022 (11:59 p.m. ET)**

**Abstract Categories:**
- **ABSTRACT CATEGORIES** (cont’d)
ABSTRACT CATEGORIES (cont’d)

CT    Clinical Trials
CT01  Clinical Trials in Progress
       Phase I clinical trials in progress
       Phase II clinical trials in progress
       Phase III clinical trials in progress
CT02  COVID-19, Cancer, and Clinical Trials
       (See also COVID01: COVID-19 and Cancer)
       Clinical trials in progress
       Phase I
       Phase II
       Phase III
       Phase IV, observational, and expanded access
CT03  First-in-Human Phase I Clinical Trials
       First-in-human phase I clinical trials
CT04  Phase I Adult Clinical Trials
       (See also ET07: Pharmacology, Pharmacogenetics, and Pharmacogenomics)
       Phase I adult clinical trials
CT05  Phase II Adult Clinical Trials
       Phase II adult clinical trials
CT06  Phase III Adult Clinical Trials
       Phase III adult clinical trials
CT07  Phase I, II, or III Clinical Trials in the Elderly
       Phase I, II, or III clinical trials in the elderly
CT08  Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations
       Phase I, II, or III clinical trials in minorities and medically underserved populations
CT09  Phase I, II, or III Clinical Trials in Pediatric Cancer
       (See also CL08: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)
       Phase I, II, or III clinical trials in pediatric cancer

EN    Endocrinology
EN01  Molecular, Preclinical, and Clinical Endocrinology
       (See also CL03: Clinical Endocrinology)
       Endocrine-related cancers
       Growth factors, receptors, and signal transduction
       Hormone receptors and diagnosis/propensity
       Hormone signaling and inhibitors
       Hormone synthesis, metabolism, and inhibitors
       Neuroendocrine and other endocrine factors
       Nuclear receptors: Structure and function
       Preclinical studies of endocrine-related cancers
       Receptors and signal transduction
       Steroid hormone receptors
       Other

ET    Experimental and Molecular Therapeutics
ET01  Biological Therapeutic Agents
       (See also CL07: Immuno-ology; IM01: Preclinical Immunotherapy)
       Antireceptors
       Apoptosis: Therapeutic manipulation
       Growth factor receptors and other surface antigens as targets for therapy
       Oncogenes, tumor suppressor genes, and gene products as targets for therapy
       Protein kinases and phosphatases as targets for therapy
       Role of microenvironment in therapeutic response
       Other
ET02  Drug Discovery
       Antibody technologies
       Biochemical modulators of the therapeutic index
       Combination chemotherapies
       Differentiation therapy
       New targets
       Novel assay technology
       Novel drug delivery systems
       Targeting the tumor microenvironment in drug development
       Other
ET03  Drug Resistance
       Drug resistance in molecular targeted therapies
       Drug transport and metabolism
       Novel mechanisms
       Regulation of gene expression in drug resistance
       Reversal of drug resistance
       Other
ET04  Gene and Vector-Based Therapy
       Antisense molecules
       Gene therapy and radiation studies
       Immune modulators
       Vector systems and targeting strategies
       Other
ET05  Mechanisms of Drug Action
       Cell cycle mechanisms of anticancer drug action
       Cellular responses to anticancer drugs
       Role of the microenvironment in therapeutic response
       Other
ET06  Molecular Targets
       Cell death pathways and treatment
       DNA damage response
       Identification of molecular targets
       Modulation of DNA repair
       Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes
       New nonclinical models for targets
       Other
ET07  Pharmacology, Pharmacogenetics, and Pharmacogenomics
       (See also CT04: Phase I Adult Clinical Trials)
       Cellular pharmacology
       Molecular pharmacology
       Pharmacogenetics and therapeutic response
       Pharmacogenomics
       Pharmacokinetics and pharmacodynamics
       Preclinical toxicology
       Other
ET08  Preclinical Radiotherapeutics
       (See also TB07: Radiation Science; CL10: Radiation Oncology)
       Interactions of new agents with radiation
       Modification of radiosensitivity
       Molecular targets of radiation response
       Normal tissue/cellular stress responses to radiation
       Radioprotectors and radiosensitizers
       Radiotherapeutic combinations
       Theranostics/radiotheranostics
       Other
ET09  Small Molecule Therapeutic Agents
       DNA-reactive agents
       Epigenetic targets
       HDAC and methyltransferase inhibitors
       Novel antitumor agents
       Novel targets and pathways
       PI3K/AKT inhibitors
       Platinum complexes
       Proteasome inhibitors
       Topoisomerases
       Tubulin agents
       Tyrosine kinase and phosphatase inhibitors
       Other

IM    Immunology
IM01  Preclinical Immunotherapy
       (See also CL07: Immuno-ology; ET01: Biological Therapeutic Agents)
       Adoptive cell therapy
       Combination immunotherapies
       Immune checkpoints
       Immune mechanisms invoked by other therapies including chemotherapy
       Immune mechanisms invoked by radiation therapy
       Immune monitoring/clinical correlates
       Immune response to therapies
       Immunomodulatory agents and interventions
       Inflammation, immunity, and cancer
       Modifiers of the tumor microenvironment
       Therapeutic antibodies, including engineered antibodies
       Vaccines (oncolytic and prophylactic)
       Other

AAMR ANNUAL MEETING 2023 • AAMR.org/AAMR2023 • #AACR23 27
IM02  Tumor Immunobiology
Adaptive immunity in tumors
Epigenetic regulation of tumor immunity
Inflammation and cancer: Metastasis
Inflammation and cancer: Tumor initiation and progression
Innate immunity to tumors
Microbiome, inflammation, and cancer
Novel animal models
Oncogenic pathway-mediated regulation of inflammation and tumor immunity
Tumor antigenicity/processing and presentation
Tumor-induced immune suppression: Extrinsic factors
Tumor-induced immune suppression: Intrinsic factors
Other

MCB04  Cellular Stress Responses
Hypoxia
Oxidative stress
Premature cellular aging
Senescence
Unfolded protein response
Other

MCB05  DNA Damage and Repair
Chromosomal structural alterations/translocations
Genomic instability
Homologous recombination
Mechanisms of genomic alterations
Radiation-induced DNA damage
Other

MCB06  Epigenetics and Epigenomics
Chromatin structure and function
DNA methylation
Epigenetic changes as molecular markers of cancer
Epigenomics
Gene silencing
Histone modification
Other

MCB07  Gene Regulation and Transcription Factors
Chromatin structure and function
Gene expression
Mechanisms of transcription
Oncogenic transcription factors
Posttranscriptional and translational control
Promoters and enhancers of transcription
Protein-protein interactions in transcription factor function
Regulation of transcription factor function
Transcriptional control of cell differentiation
Other

MCB08  Genomics (See also BCS01: Bioinformatics, Computational Biology, and Systems Biology)
Functional genomics
Genomic profiling of tumors
High-throughput sequencing
Large-scale approaches to cancer gene discovery
Microarrays
Other

MCB09  Metabolism and Cancer
Metabolic pathways
Metabolomics
Mitochondrial function
Signaling pathways that regulate metabolism
Other

MCB10  microRNAs and Other Noncoding RNAs
Epigenetic control of miRNA expression
miRNA profiling in cancer
miRNA regulation of cancer biology
miRNA-based diagnostics
miRNA-based therapeutics
miRNAs as tumor suppressors/oncogenes
Noncoding RNAs
Other

MCB11  Oncogenes and Tumor Suppressor Genes
Cytoplasmic signal transducers
Genotype/phenotype correlations
Nuclear oncoproteins and tumor suppressor genes
Oncogene growth factors and their receptors
Tumor suppressor genes
Other

MCB01  Cell Cycle
CDKs and CDK inhibitors
Cell cycle checkpoints
Control of cell cycle progression
Telomeres and telomerase
Other

MCB02  Cell Death
Apoptosis
Autophagy
Bcl-2 family proteins
Caspases
Effects on mitochondria/mitochondrial function
Inhibitor of apoptosis (IAP) family proteins
Necrosis and necroptosis
Transcriptional control of apoptosis
Other

MCB03  Cell Growth Signaling Pathways
Cell signaling
Cell-cell interactions
Growth factors
GTPases, their regulators, and effectors
Kinases and phosphatases
Receptors
Tumor-stromal cell interactions
Ubiquitin and ubiquitin-like proteins
Other

MCB09  Metabolism and Cancer
Health services and comparative effectiveness research
Implementation science
Infection and immune factors
Next-generation sequencing in epidemiology studies (whole genome, exome, targeted, or fine-mapping)
Pathway and candidate gene studies of risk or prognosis
Pharmacoepidemiology
Prenecrotic and tumor markers
Primary and secondary intervention studies
Psychosocial and behavioral epidemiology
Risk prediction models for incidence, prognosis, and/or mortality
Screening and early detection
Statistical and epidemiological methodology
Survivorship research
Other

PR  Prevention, Early Detection, and Interception
Application of molecular pathology in clinical prevention
Biomarkers and intervention studies
Cancer disparities research
Cancer surveillance and screening studies
Chemoprevention clinical trials
Genomics and proteomics in cancer risk and response assessment
Infections and virus-related cancers
Microbiome and prevention
Obesity, diet, physical activity, and energy balance
Prevention and treatment of premalignant lesions (intraepithelial neoplasia)
Prevention of second cancers
Quality of life/late effects/survivorship
Recruitment of racial and ethnic minorities and other underserved populations in clinical prevention trials
Screening and early detection
Other

PS  Population Sciences
(包括Diversity, Equity, and Inclusion)

PR01  Clinical Prevention, Early Detection, and Interception
(包括Diversity, Equity, and Inclusion)

BCS01  Bioinformatics, Computational Biology, and Systems Biology

February 28, 2023
ABSTRACT CATEGORIES (cont’d)

PR02 Preclinical Prevention, Early Detection, and Interception
Animal models in prevention
Behavioral sciences and prevention
Biological and biochemical mechanisms in prevention
Biomarkers and intervention studies
Cancer communication and decision making
Cellular models
Chemoprevention studies
Diet, nutrition, and cancer
Microbiome and prevention
Molecular markers in prevention research
Molecular targets for prevention
New agent development
Screening and early detection
Other

TB Tumor Biology
TB01 Angiogenesis
Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other
TB02 Carcinogenesis
Chemical, environmental, and virus-induced carcinogenesis
Mutagenesis
Other
TB03 In Vivo Imaging (See also CL14: Translational Research: Molecular Biology in Clinical Oncology)
Advanced nanotechnology and imaging
Application of imaging technology to the clinic
Imaging in animal models
Imaging of molecular and cellular events in the tumor microenvironment
Imaging of molecular and cellular events in tumors and tumor cells
Imaging the immune response
Imaging tumor metabolism
New targets for imaging
Other
TB04 Metastasis
Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis-promoting genes
Metastasis suppressor genes
Premetastatic niche
Therapeutic metastasis prevention
Other
TB05 Nonclinical Models of Cancer
3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organoids
Other animal and cell models of cancer
Patient-derived xenograft models
Zebrafish models of cancer
Other
TB06 Pediatric Cancer - Basic Science (See also CL08: Pediatric Cancer - Clinical Investigations; CT09: Phase I, II, or III Clinical Trials in Pediatric Cancer)
Developmental origins and drivers of pediatric cancer
Pediatric cancer genomics and epigenomics
Pediatric cancer models
Pediatric cancer tumor microenvironment and tumor heterogeneity
Other
TB07 Radiation Science (See also CL10: Radiation Oncology; ET08: Preclinical Radiotherapeutics)
Modulators of radiation response
Photobiology/photodynamic therapy
Radiation dose fractionation
Radiation-activated signaling pathways
Radiation-induced gene expression
Radiation-induced resistance
Radiobiology research
Radioprotectors and radiosensitizers
Other
TB08 Stem Cell Biology
Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cells and regenerative medicine in oncology
Other
TB09 Tumor Adhesion
Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other
TB10 Tumor Evolution and Heterogeneity
Causes and consequences of tumor heterogeneity
Clonal evolution
Complex adaptive systems
Methods to measure tumor evolution and heterogeneity
Other
TB11 Tumor Microenvironment
Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

RSP Regulatory Science and Policy
RSP01 Regulatory Science and Policy
Biosimilars and generics
Clinical trial design and accrual
Combination therapies and codevelopment of investigational agents and diagnostics
Data science and informatics
International regulatory issues
Novel endpoints and biomarkers
Real-world evidence and retrospective analyses
Tobacco and e-cigarette regulation
Other

SHP Science and Health Policy
SHP01 Science and Health Policy
Cancer disparities
Cancer survivorship
Implementation science
Patient advocacy and engagement
Value and cost issues in cancer care
Other

Regular Abstract Submission Deadline: November 17, 2022 (11:59 p.m. ET)
Late-Breaking and Clinical Trials Abstract Submission Deadline: January 12, 2023 (11:59 p.m. ET)
AACR Membership: The Essential Association for You

With over 52,000 members in 130 countries and territories around the world and over 32% of members living outside the United States, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to both senior and early-career investigators who conduct cancer research and related biomedical science, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR’s vision and support our mission to prevent and cure cancer.

AACR membership promotes the professional growth of those in training, facilitates collaborations for established scientists, and supports everyone working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit AACR.org/International.

Membership Application Deadlines for Abstract Sponsorship

AACR members have the exclusive benefit of being able to sponsor and endorse abstracts for presentation at the AACR Annual Meeting. Members must be in good standing (dues paid or eligibility recertified) in order to take advantage of this member privilege. (Refer to page 23 for full details and instructions on sponsoring an abstract.)

Nonmember individuals interested in joining the AACR and sponsoring an abstract must submit an application for membership no later than November 11, 2022. Individuals interested in joining the AACR and sponsoring a late-breaking abstract must submit an application for membership no later than January 6, 2023.

AACR members play an integral role in achieving our mission and in advancing cancer research. We encourage our Active, Emeritus and Honorary members to nominate colleagues, students, nurses, technicians, and others working in support of cancer research to join the AACR today!

Abstract Sponsorship

Membership Application Deadlines
November 11, 2022
January 6, 2023

Abstract Submission Deadlines
November 17, 2022
January 12, 2023
(Late-Breaking and Clinical Trials)

Scholar Awards

Award
Scholar-in-Training
Global Scholar-in-Training
AACR Minority and Minority-Serving Institution Faculty (MMSIF) Scholar in Cancer Research Awards
AACR Minority Scholar in Cancer Research Awards
AACR-Women in Cancer Research (WICR) Scholar Awards
AACR Undergraduate Scholar Awards

Application Deadline
November 17, 2022
November 17, 2022
December 2, 2022
December 2, 2022
December 2, 2022
December 2, 2022

Contact the AACR Membership Department with any questions at 215-440-9300 or membership@aacr.org.
AACR Membership Categories

**Active Membership** is open to investigators who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

**Affiliate Membership** is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

**Associate Membership** is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. Annual dues are not required. (Important reminder: Associate members are required to recertify their eligibility in order to remain on the member rolls. Please log into myAACR to retain your member exclusive benefits!)

**Student Membership** is open to persons who have an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor’s degree. Annual dues are not required.

**Sustaining Membership** is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission and activities of the AACR. Annual dues are determined by the Sustaining Member level.

**Emeritus Membership** is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

**Honorary Membership** is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

AACR Member Exclusive Benefits

**Early Access to AACR Annual Meeting Housing Reservations**

Tuesday, September 27, 2022, (opens at 9:00 a.m. U.S. ET) through Monday, October 3, 2022

As a member exclusive benefit, AACR members in good standing (dues paid through December 31, 2022) are eligible to reserve hotel accommodations for the AACR Annual Meeting 2023 before reservations open to all attendees. Members may log into AACR.org/myAACR to check dues status and make a payment using the secure AACR site.

**Hotel Reservations**

CMR (Convention Management Resources) is the official hotel management company for the AACR Annual Meeting.

One hotel reservation is allowed per member effective September 27, 2022. Housing reservations open to the general public on October 4, 2022 (see pages 35-36). Members will need to provide the following information in order to secure a reservation:

- AACR member ID number
- Last name (as it appears in the AACR Membership records)

Members are encouraged to take advantage of early access to housing reservations before housing is made available to all attendees. Please contact the Membership Department at membership@aacr.org or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at AACR.org/myAACR and join us in the global conquest of cancer.

The AACR is aware that one or more unauthorized companies are using deceptive advertising methods to direct users to fraudulent websites that purport to offer housing and registration for the AACR Annual Meeting 2023. Please note that AACR.org/AACR2023 is the only website through which users can register to attend the AACR Annual Meeting and confirm a hotel room. AACR cannot guarantee your registration or housing if you purchase using an illegitimate website.
AACR MEMBERSHIP OPPORTUNITIES (cont’d)

Membership Information Hub
The Membership Information Hub is a home base for AACR members and individuals interested in becoming members. Visit the Hub to learn more about AACR’s events, programs, and activities, during the meeting. Attendees are encouraged to engage with colleagues from around the world, join Association groups, become more involved in AACR programs and activities, and share member experiences.

Membership Center
The AACR Membership Center provides a place where members can obtain information regarding their membership, join Association groups within the AACR, update contact information, pay annual dues, transfer to other categories of membership, and become familiar with new membership services.

Membership Booth at Registration
The Membership Booth in the Registration Area is a service center for AACR members to register, pay their dues, and learn more about membership during the meeting. Nonmembers are encouraged to take advantage of the special offer to join the AACR prior to registering for the meeting. Visit the Membership Booth at Registration for more details.

Member Appreciation Events
New Member Networking Mixer
The AACR is extremely pleased to host a New Member Networking Mixer each year to welcome newly elected members into the association and provide them with an opportunity to meet and interact with the AACR leadership, network with colleagues and forge new relationships, and learn more about exclusive member benefits and how to get involved in the association.

Celebrating AACR Long-Term Members:
Member Appreciation Breakfast
The AACR is extremely pleased to recognize those scientists who have been members of the association for 25 years and more. The AACR board of directors extends its sincere and heartfelt thanks to these members for their devotion to cancer research and long participation in and support of the AACR.

Meet the 2023-2024 AACR President
The Meet the 2023-2024 AACR President event provides an opportunity for AACR members and Annual Meeting attendees to meet informally with the 2023-2024 AACR President, Dr. Philip D. Greenberg, to congratulate him on his presidency and ask general questions.

AACR 50-Year Members and Honorary Members
It is the AACR’s privilege to honor those scientists who have reached the milestone of 50 years of AACR membership. The AACR Board of Directors would like to extend their sincere thanks and appreciation to these members for their dedication to cancer research and continued participation in and support of the AACR’s activities and programs. These distinguished members will be formally honored at the Annual Business Meeting of Members and celebrated throughout the meeting.

Supporting Diversity, Equity, and Inclusion
The AACR strives to support the professional development and career advancement of underrepresented minority and women scientists in cancer research. Through the efforts of AACR-Minorities and Cancer Research and AACR-Women in Cancer Research, the AACR is working to increase the number, participation, visibility, and recognition of investigators through various initiatives.

AACR-Minorities in Cancer Research (MICR)
Minorities in Cancer Research (MICR) is a membership group within the AACR committed to preventing and curing cancer and eradicating cancer health disparities while meeting the professional needs and advancing the careers of minority scientists. It is led by the MICR Council, which is the advisory body to the AACR leadership on issues of concern to minority investigators and is also responsible for spearheading initiatives and organizing activities of MICR through its committees.
MICR will present several exciting and engaging activities during the AACR Annual Meeting, including:

- **MICR Networking and Resource Center.** The MICR Networking and Resource Center provides meeting attendees with a comfortable environment to network one-on-one and in small groups while learning about AACR and MICR programs as well as MICR membership and committee service opportunities.

- **MICR Scientific Symposium.** This session informs the cancer research community about cancer issues related to race and ethnicity and provides a platform for minority scientists to present their work with discussion.

- **MICR Career Development Forum.** This session provides useful tools and information to support the professional development of minority cancer researchers.

- **MICR Town Hall.** This session provides an opportunity for all attendees who support MICR to join the MICR Council in an informal discussion about current topics that have an impact on the cancer community and underrepresented minorities.

- **MICR Distinguished Lectureship Series.** The AACR-MICR Distinguished Lectureship Series currently takes place twice a year in conjunction with the AACR Annual Meeting and again during the Annual Conference on the Science of Cancer Health Disparities. The intention of this series is to invite leading researchers to provide scientific presentations to faculty and students of Minority-Serving Institutions (MSIs) so as to bring the latest science directly to faculty and students on their campuses in the host city of the conference.

- **MICR Minority and Minority-serving Faculty Assembly.** This gathering will provide an open forum for early- and mid-stage investigators who are minority faculty and faculty at Minority-Serving Institutions and members of the MICR Council to meet and discuss their challenges, needs, and opportunities, and how the AACR and MICR can help with addressing them.

- **MICR Meet and Greet.** All AACR Annual Meeting attendees are invited to informally network with the MICR Council, Committee Members, and Scholar Awardees for one-on-one or group discussions.

- **MICR Scholar Award Programs.** Focuses on underrepresented minority early-career researchers and faculty, as well as faculty at Minority-Serving Institutions.

All annual meeting attendees and MICR members are invited to learn more about MICR programs, committees, and other programs of interest by visiting [AACR.org/MICR](http://AACR.org/MICR) or emailing micr@aacr.org. Nonmembers are welcome to visit and join.

---

**AACR-Women in Cancer Research (WICR)**

Women in Cancer Research (WICR) is a membership group within the AACR committed to recognizing women’s scientific achievements and fostering their career development and advancement in cancer research. It is led by the WICR Council, the advisory body to the AACR leadership on issues of concern to women investigators, which is also responsible for organizing the activities of WICR through its committees.

WICR activities taking place during the Annual Meeting include:

- **WICR Career Development Forum.** This session provides useful tools and information to support the professional development of women investigators.

- **WICR Networking and Resource Center.** The WICR Networking and Resource Center provides meeting attendees with a comfortable environment to network one-on-one and in small groups while learning about AACR and WICR programs as well as WICR membership and committee service opportunities.

- **WICR Meet and Greet.** All AACR Annual Meeting attendees are invited to informally network with the WICR Council, Committee Members, and Scholar Awardees for one-on-one or group discussions.

- **WICR Scholar Award Program.** The WICR Scholar Award supports the participation of young investigators to attend the AACR Annual Meeting. These awards are given annually to members of Women in Cancer Research who are scientists-in-training and presenters of meritorious scientific papers at this AACR Annual Meeting.

All AACR Annual Meeting attendees and WICR members are invited to learn more about WICR programs, committees, and other programs of interest by visiting [AACR.org/WICR](http://AACR.org/WICR) or emailing wicr@aacr.org. Nonmembers are welcome to visit and join.

---

**Supporting AACR Associate Members (Early-Career Researchers/Scientists)**

With over 25,000 Associate members, the AACR supports the education, training, and professional development of early-career researchers/scientists who are graduate students, medical students and residents, and clinical and postdoctoral fellows, in the cancer field.

The **AACR Associate Member Council (AMC)** are Associate members of the AACR who are elected to serve as an advisory body to the AACR leadership and to address the needs and concerns of early-career researchers/scientists. The AMC works to support the AACR’s mission to prevent and cure cancer by promoting the professional development of early-career researchers/scientists throughout the world and encouraging Associate member recruitment, retention, and engagement.
Opportunities for Associate Members During the AACR Annual Meeting

Some key AACR Annual Meeting programs for Associate members include the Professional Advancement Series Sessions, special sessions featuring AACR senior scientists and recently transitioned early-stage cancer investigators, and more. Opportunities for Associate members taking place during the AACR Annual Meeting include:

• Career Discussions. Organized by the AMC, these informal networking and discussion sessions are designed for early-career researchers to interact with recently transitioned physician-scientist and junior faculty/equivalent peers around various career topics.

• Associate Member Meet and Greet. Associate members can meet and network with other early-career attendees and Council members.

• Early-Career Associate Members 5K Team. Join the Early-Career Associate Members team and participate in the AACR Runners for Research 5K Run/Walk, build relationships among colleagues, and raise awareness and funds to support cancer research.

• Recognition and Scholar Awards. The AACR offers several scholar awards to meritorious early-career researchers residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Please refer to pages 17-18.

Science Education for the Next Generation of Cancer Researchers (Opportunities for high school and undergraduate students)

AACR Undergraduate Scholar Awards

In its 26th year, this award program is highly competitive and intended to inspire young, third-year science students to enter the field of cancer research and to provide a unique educational opportunity for these students in the development of their careers in science. To learn more about this award program, visit AACR.org/UndergradAwards. Application deadline: December 2, 2022.

18th Annual Undergraduate Student Caucus and Poster Competition

With more than 250 undergraduate student participants every year, the AACR Undergraduate Student Caucus and Poster Competition continues to be the premier event for undergraduate students attending the AACR Annual Meeting. Now in its 18th year, this program provides undergraduate students with the opportunity to learn more about current research in the cancer field, hear from investigators about educational pathways and career development, explore career options in the cancer field, and compete for the Margaret Foti Foundation Undergraduate Prizes for Cancer Research while presenting research. Undergraduates at all levels are welcome to participate in this highly anticipated program at no cost. To learn more about this exciting opportunity, please visit AACR.org/ScienceEducation or send an email to scienceeducation@aacr.org.


AACR Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers

The Special Program for High School Students promotes interactions between senior cancer scientists and promising students in order to facilitate the contributions of these students to scientific research and the conquest of cancer. Don’t miss this wonderful opportunity to learn about cancer research and careers in biomedical research and medicine. The session is free, but space is limited. Learn more at AACR.org/HighSchoolProgram. Registration Deadline: March 10, 2023.
Hotel Reservations

CMR (Convention Management Resources) is the official hotel management company for the AACR Annual Meeting.

Hotel reservations for the AACR Annual Meeting 2023 will open at 9:00 a.m. U.S. ET on Tuesday, September 27, 2022, for all AACR members in good standing. Housing for nonmember attendees will open at 9:00 a.m. on Tuesday, October 4, 2022. The deadline for making hotel reservations is Friday, March 3, 2023. After the deadline, registrants may be required to make their own housing arrangements.

You may reserve your hotel room in one of the following ways:

Online: Visit the AACR Annual Meeting website at AACR.org/AACR2023 to reserve your hotel room online. Please note that you must supply a credit card in order to reserve a room online. You will find descriptions, amenity information, and photographs for each AACR official hotel. Additionally, a map showing the location of all hotels and the Orange County Convention Center is available on the AACR Housing website. Visit the AACR Housing website to get up-to-the-minute availability and receive immediate confirmation of your hotel reservation.

Phone: AACR Housing agents will be available to accept reservations as well as provide information on the official AACR hotels Monday through Friday from 9:00 a.m. to 9:00 p.m. U.S. ET. You will be required to supply a credit card if you reserve your hotel room by phone. Once your reservation is complete, you will receive immediate confirmation by email. AACR Housing can be reached toll-free in the U.S. and Canada at 888-381-7166 or for international callers at 415-293-4397. When calling AACR Housing be certain to have the following information:

- Arrival and departure dates
- Hotel preferences
- Credit card number
- Your address, phone number, fax number, and email address
- Any special requests

Guarantee

Reservations must be guaranteed with either a major credit card (AMEX, Visa, or MasterCard) or a check in the amount of $300 per guestroom and $700 per suite. Make checks payable to Convention Management Resources, Inc. If using a credit card, the card will not be charged until the check-out date. You must present a credit card upon check-in.

Changes and Cancellations

Changes and cancellations can be made:

- Online at the AACR Housing website at AACR.org/AACR2023
- By emailing your change or cancellation to AACRSupport@cmrus.com
- By calling AACR Housing at 888-381-7166 or 415-979-2262
- By faxing your change or cancellation to 415-293-4397

Your credit card will be charged one night’s room plus tax or your check deposit will be forfeited if you cancel your reservation less than 72 hours before your confirmed arrival date. If you fail to arrive on the date confirmed by AACR Housing, your credit card will be charged one night’s room plus tax or your check will be forfeited. All subsequent nights of the reservation will be cancelled.
Hospitality Suites
Suites are for sleeping accommodation only and may not be used for meetings or events without prior written permission from AACR. For these types of events, please complete the AACR Affiliate Event Space Request Form. If you would like a copy of this form, please contact AACR Housing at 888-381-7166, 415-979-2262, or via email at AACRSupport@cmrus.com.

Group Reservations
Organizations wishing to hold a block of rooms must use the Group Housing Form, which can be obtained by visiting AACR.org/AACR2023 and clicking on the Housing link. Exhibitors may request rooms in the AACR room block and must submit an Exhibitor Room Block Request Form, which can be accessed from AACR.org/AACR2023. Please adhere to all rules and regulations to facilitate processing. Confirmation will be emailed.

The AACR is aware that one or more unauthorized companies are using deceptive advertising methods to direct users to fraudulent websites that purport to offer housing and registration for the AACR Annual Meeting 2023. Please note that AACR.org/AACR2023 is the only website through which users can register to attend the AACR Annual Meeting and confirm a hotel room. AACR cannot guarantee your registration or housing if you purchase using an illegitimate website.

“The best conference I have ever attended. Perfectly organized and executed.”
Air Transportation

The Orlando International Airport (airport code: MCO) is the major airport in the Orlando Region and offers multiple U.S. and international flights daily. Orlando is also served by Amtrak.

Travel Office: Corporate Traveler
Email: samantha.baron@corporatetraveler.us
$30 service fee applies
Business hours: Monday-Friday, 8:00 a.m. to 6:00 p.m. ET

Assistance for International Travelers

An official letter of invitation is available through the online registration system. Contact the American Consulate in your country to review the current regulations for travel to the United States. Please begin the visa application process as early as possible. Information is available on the U.S. Department of State website at www.travel.state.gov.

Ground Transportation

Taxi Service

Orlando International Airport is located 12 miles from the Orange County Convention Center. Many companies provide taxicab service at Orlando International Airport. If you need a taxi, simply follow the signs leading to the Ground Transportation Curb (Level 1). A customer service representative will place you with the first available taxi, unless you specify a particular taxicab company.

Public Transportation

LYNX is the public transit provider for Orange County. To see LYNX fare and pass options, visit: golynx.com/maps-schedules/

Airport Shuttle

The Mears Orlando Shuttle Service is the official ground transportation for Orlando International Airport. Mears shuttle service is an economical transportation option for individual travelers and for groups as the fare includes all tolls and other surcharges.

Shuttle vans are located in Terminal A and B on the Ground Transportation Level (Level 1) at commercial parking spaces, A19-A21 and B27-B29.

Shuttle van fares are charged per person. Check with the attendant on-site for round-trip fares. You can also schedule your reservation ahead of time by visiting the Mears Orlando Shuttle Service Website (www.mearstransportation.com/orlando-shuttle-service) or by calling 407-423-5566.

AACR Shuttle Service

The AACR will provide complimentary shuttle service over the meeting dates for all official AACR Annual Meeting hotels that are not within walking distance of the Orange County Convention Center. When available, the hotel shuttle schedule will be posted on AACR.org/Travel and will include shuttle hours of operation and the designated route number for each hotel.
Opportunities to Support the AACR Foundation

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact Holly Rush at 215-446-7192 or email at corporaterequests@aacr.org.

Fellows of the AACR Academy

The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

The AACR Academy is currently led by Dr. Charles L. Sawyers (2021-2023 AACR Academy President) and a Steering Committee of additional Fellows who serve as the collective voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of prestigious Fellows of the AACR Academy will be formally recognized during the AACR Annual Meeting 2023 Opening Ceremony, scheduled to take place on Sunday, April 16.

AACR Scientific Achievement Awards, Lectureships, and Prizes

Since 1961, the AACR has been proud to recognize scientific excellence across the spectrum of basic, translational, clinical, and epidemiological cancer research through a robust collection of annual awards and lectureships that serve to honor laboratory researchers, physician-scientists, and population scientists who have made significant contributions to our understanding of the diagnosis, prevention, and treatment of cancer. All annual award recipients are honored during the AACR Annual Meeting, and the majority are invited to present featured lectures during the meeting.

A complete listing of 2023 awards and nomination deadlines is provided below. Visit AACR.org/Awards to learn more and to nominate your colleagues!

Nomination Submission Deadline: Thursday, September 15

- AACR Award for Lifetime Achievement in Cancer Research
- AACR Award for Outstanding Achievement in Basic Cancer Research
- AACR Award for Outstanding Achievement in Blood Cancer Research
- AACR Award for Outstanding Achievement in Chemistry in Cancer Research
- AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
- AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research
It was great getting back to see friends and meet colleagues in person. I had a great time! Also, being able to access the talks virtually really helped me to see more of the meeting because there are so many talks I miss when everything’s only in person.
AACR ANNUAL MEETING 2023 COMMITTEES

AACR Annual Meeting Program Committee

Chair
Robert H. Vonderheide

Vice Chairs
Lucile L. Adams-Campbell
Carlos M. Caldas
José R. Conejo-García
Benjamin L. Ebert
Peter Kuhn
Shivaani Kummar
Quynh-Thu Le
Christine M. Lovly
Sanjay V. Malhotra
Motomi Mori
Eileen M. O’Reilly
Seishi Ogawa
Anna Karolina Palucka
Sylvia K. Plevritis
Joachim Rudolph
John H. Stewart IV
Josep Taberner
Sarah K. Tasian
Judith A. Varner
Matthew G. Vander Heiden
Teresa A. Zimmers

Cochairs
Iannis Aifantis
Ido Amit
Andrew T. Chan
Alan D. D’Andrea
Matthew J. Ellis
Rebecca Fitzgerald
Kevin L. Gardner
Andrew K. Godwin
Jeremy Goepcks
Romina Goldszmid
Carmen E. Guerra
Dawn L. Hershman
Trey Ideker
Jan Kitajewski
Harriet M. Kluger
Mignon Lee-Cheun Loh
Grzegorz S. Nowakowski
Taofeek K. Owonikoko
Ruben A. Mesa
Kathleen N. Moore
Marina Pasca di Magliano
Elizabeth A. Platz
Avery D. Posey, Jr.
Gabriel A. Rabinovich
Kimberly Stegmaier
Sheila A. Stewart
Chau Trinh-Shevrin
Mary Jo Turk
Cornelia M. Ulrich
Colonel James E. Williams, Jr.
Bradly G. Wouters
Timothy A. Yap
Clayton C. Yates
Jinghui Zhang

AACR Annual Meeting Clinical Trials Committee

Cochairs
Shivaani Kummar
Timothy A. Yap

Members
Nita Ahuja
William S. Dalton
Ruggero De Maria
Patrick M. Forde
Susan Halabi
Roy S. Herbst
Virginia G. Kaklamani
Steven K. Libutti
Robert G. Maki
Ignacio Melero
Ruben A. Mesa
Pamela N. Munster
D. William Parsons
Akash Patnaik
Stephen C. Rubin
Howard I. Scher
Padmanee Sharma
Weijing Sun
Sara M. Tolaney
Nicholas C. Turner
Zev A. Wainberg

Additional appointments pending
AACR ANNUAL MEETING 2023
COMMITTEES (cont’d)

AACR Annual Meeting Education Committee

Chairs
Carlos M. Caldas
Anna Karolina Palucka

Cochairs
Elizabeth A. Platz
Sheila A. Stewart
Judy A. Varner

Members
Raza Ali
Olga A. Anczuków-Camarda
Alberto Bardelli
Maria Casanova-Acebes
Roberta Faccio
Stacey D. Finley
Claudia Fischbach
H. Courtney Hodges
Lilian Kabeche
Anusha Kalbasi
Leeat Keren
Christopher I. Li
Amanda W. Lund
Sandra S. McAllister
Dominique S. Michaud
Muhammad Murtaza
Erik Sahai
Maria S. Sosa
Eliezer M. Van Allen

AACR Exhibits Committee

Chair
Wafik S. El-Deiry

Members
Ana Luisa Correia
Laura M. Heiser
Amanda W. Lund
Esther A. Obeng
Feyruz V. Rassool
Rachel M. Syme
Ruoning Wang
Iain D. G. Watson

AACR Continuing Medical Education Committee

Chair
Steven T. Rosen

Members
Sarki A. Abdulkadir
Antonio T. Fojo
Karen A. Gelmon
Daniel A. Laferlu
Jennifer W. Mack
Jean L. Nakamura
Evan Y. Yu
Additional appointments pending

AACR Satellite Educational Symposia Committee

Appointments pending

“Excellent opportunity to stay abreast of advances in understanding of cancer biology.”